MLex Comment: FTC unlikely to accept divestiture in Grifols,Talecris blood plasma deal
Lawyers for rival blood plasma companies Grifols of Spain and Talecris recently presented a proposed divestiture for staffers at the Federal Trade Commission, but even that seems to have little likelihood...To view the full article, register now.
Already a subscriber? Click here to view full article